Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes

2017 ◽  
Vol 17 (10) ◽  
Author(s):  
Ali Cinar
Keyword(s):  
Type 1 Diabetes ◽  
Artificial Pancreas

A Qualitative Study of the Views of Individuals With Type 1 Diabetes on the Ethical Considerations Raised by the Artificial Pancreas

2020 ◽  
Vol 10 (3) ◽  
pp. 237-261
Author(s):  
Ariane Quintal ◽  
Virginie Messier ◽  
Rémi Rabasa-Lhoret ◽  
Eric Racine
Keyword(s):  
Type 1 Diabetes ◽  
Qualitative Study ◽  
Artificial Pancreas ◽  
Ethical Considerations

Dual‐hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions

2021 ◽  
Author(s):  
Marco Infante ◽  
David A. Baidal ◽  
Michael R. Rickels ◽  
Andrea Fabbri ◽  
Jay S. Skyler ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Recent Progress ◽  
Artificial Pancreas ◽  
Future Directions

scholarly journals The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day

2018 ◽  
Vol 12 (2) ◽  
pp. 273-281 ◽  
Author(s):  
Roberto Visentin ◽  
Enrique Campos-Náñez ◽  
Michele Schiavon ◽  
Dayu Lv ◽  
Martina Vettoretti ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
In Silico ◽  
Artificial Pancreas ◽  
Real Life ◽  
Glucose Monitoring ◽  
Glucose Variability ◽  
Self Monitoring ◽  
Inhaled Insulin ◽  
Single Meal

Background: A new version of the UVA/Padova Type 1 Diabetes (T1D) Simulator is presented which provides a more realistic testing scenario. The upgrades to the previous simulator, which was accepted by the Food and Drug Administration in 2013, are described. Method: Intraday variability of insulin sensitivity (SI) has been modeled, based on clinical T1D data, accounting for both intra- and intersubject variability of daily SI. Thus, time-varying distributions of both subject’s basal insulin infusion and insulin-to-carbohydrate ratio were calculated and made available to the user. A model of “dawn” phenomenon based on clinical T1D data has been also included. Moreover, the model of subcutaneous insulin delivery has been updated with a recently developed model of commercially available fast-acting insulin analogs. Models of both intradermal and inhaled insulin pharmacokinetics have been included. Finally, new models of error affecting continuous glucose monitoring and self-monitoring of blood glucose devices have been added. Results: One hundred in silico adults, adolescent, and children have been generated according to the above modifications. The new simulator reproduces the intraday glucose variability observed in clinical data, also describing the nocturnal glucose increase, and the simulated insulin profiles reflect real life data. Conclusions: The new modifications introduced in the T1D simulator allow to extend its domain of validity from “single-meal” to “single-day” scenarios, thus enabling a more realistic framework for in silico testing of advanced diabetes technologies including glucose sensors, new insulin molecules and artificial pancreas.

Super twisting sliding mode control algorithm for developing artificial pancreas in type 1 diabetes patients

2017 ◽  
Vol 38 ◽  
pp. 200-211 ◽  
Author(s):  
Sayyar Ahmad ◽  
NasimUllah ◽  
Nisar Ahmed ◽  
Muhammad Ilyas ◽  
Waqas Khan
Keyword(s):  
Type 1 Diabetes ◽  
Sliding Mode Control ◽  
Control Algorithm ◽  
Sliding Mode ◽  
Artificial Pancreas ◽  
Mode Control ◽  
Diabetes Patients

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

2021 ◽  
Author(s):  
Coralie Amadou ◽  
Sylvia Franc ◽  
Pierre-Yves Benhamou ◽  
Sandrine Lablanche ◽  
Erik Huneker ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Adverse Events ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Real Life ◽  
Serious Adverse Events ◽  
Life Conditions ◽  
Time In Range

<b>OBJECTIVE </b> <p>To analyze safety and efficacy of the DBLG1 hybrid closed-loop artificial pancreas system in patients with Type 1 Diabetes in real life conditions. </p> <p> </p> <p><b>METHODS</b></p> <p>Following a one-week run-in period with usual pump, 25 patients were provided with the commercial DBLG1 system. We present the results of Time-in-Range and HbA1c over a 6-month period.</p> <p><b> </b></p> <p><b>RESULTS</b></p> <p>The mean (SD;range) age of patients was 43 years (13.8; 25-72). At baseline, mean HbA1c and TIR 70-180mg/dL were respectively 7.9% (0.93; 5.6- 8.5) [63mmol/mol (10; 38-69)] and 53% (16.4;21-85). One patient stopped using the system after 2 months. At 6-month, mean HbA1c decreased to 7.1% [54mmol/mol] (p<0.001) and TIR 70-180mg/dL increased to 69.7% (p<0.0001). TIR<70mg/dL decreased from 2.4 to 1.3% (p=0.03). TIR<54mg/dL decreased from 0.32 to 0.24% (p=0.42). No serious adverse event was reported during the study. </p> <p> </p> <p><b>CONCLUSION</b></p> <p>The DBLG1 System confirms its ability to significantly improve glycemic control in real life conditions, without serious adverse events. </p>

Sign in / Sign up

Export Citation Format

Share Document